Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 16/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16855449 | 0.88 | ADRA1A (0.64) | ADRA1AALDH1A1 | |
| SCHEMBL20052796 | 0.88 | ADRA1A (0.79) | ADRA1AKDM4EALDH1A1 | |
| SCHEMBL20052743 | 0.83 | ADRA1A (0.64) | ADRA1AKDM4EALDH1A1 | |
| SCHEMBL16835561 | 0.79 | ADRA1A (0.68) | ADRA1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL22360345 | 0.77 | ADRA1A (0.60) | ADRA1A | |
| SCHEMBL16846280 | 0.76 | ADRA1A (1.00) | ADRA1AKDM4EALDH1A1 | |
| SCHEMBL18186148 | 0.75 | ADRA1A (0.52) | ADRA1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL18186147 | 0.75 | ADRA1A (0.67) | ADRA1A | |
| SCHEMBL16855260 | 0.75 | ADRA1A (0.79) | ADRA1A | |
| SCHEMBL16824482 | 0.75 | ADRA1A (0.80) | ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961221-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-30 | — | — | US | disclosed |
| US-20200230136-A1 | SELECTIVE ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS ALONE, OR IN COMBINATION WITH CHYMASE INHIBITORS FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF PERIPHERAL ARTERY DISEASES (PAD) | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | US | disclosed |
| US-10323020-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-06-18 | — | — | US | disclosed |
| EP-3083592-B1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES AND THEIR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS | Bayer Pharma AG (DE) | 2018-06-27 | — | — | EP | disclosed |
| US-20180141930-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200230136-A1 | SELECTIVE ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS ALONE, OR IN COMBINATION WITH CHYMASE INHIBITORS FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF PERIPHERAL ARTERY DISEASES (PAD) | ADRA2C, ADRB2, ADRA2A | ADRA1A 9/4885KDM4E 4636/4885ALDH1A1 800/4885 |
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885KDM4E 3729/4885ALDH1A1 2621/4885 |
| US-10323020-B2 | Substituted piperidinyl tetrahydroquinolines | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885KDM4E 3729/4885ALDH1A1 2621/4885 |
| US-10961221-B2 | Substituted piperidinyl tetrahydroquinolines | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885KDM4E 3729/4885ALDH1A1 2621/4885 |
| US-20180141930-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885KDM4E 3729/4885ALDH1A1 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.